Zanamivir: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 33: | Line 33: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Antiviral]] | ||
[[Category:Wikinfect]] | [[Category:Wikinfect]] | ||
Revision as of 20:03, 29 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Zanamivir (INN) (IPA: Template:IPA) is a neuraminidase inhibitor used in the treatment of and prophylaxis of both Influenzavirus A and Influenzavirus B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza. Relenza is the only type of Zanamivir.
Category
Antiviral
US Brand Names
RELENZA®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages